Aflibercept in diabetic macular oedema: Added benefit not proven

There were no relevant differences between the treatment groups for patients in whom the area of greatest visual acuity is also affected. For other patients, data were lacking. —> Read More Here

facebooktwittergoogle_plusredditpinterestlinkedinmail

Leave a Reply

Your email address will not be published. Required fields are marked *